Citations

Showing 10 of 108135 citations.

An Uncommon Case of Small Bowel and Pancolonic Varices
Baldwin, Nicholas, Ravi, Sujan, Shoreibah, Mohamed , Kamath, Patrick S.

Mayo Clinic

ACG Case Reports Journal | October 4, 2021 | Volume: 8 | Issue: 9 | Pages: e00666

10.14309/crj.0000000000000666 | PMID 34621911 Get It

The Calorimetric Method of Determining Blood Flow in the Extremities
Sheard, Charles

Mayo Clinic

Science | October 4, 2021 | Volume: 64 | Issue: 1661 | Pages: 427-428

10.1126/science.64.1661.427-c Get It

Safety and efficacy of microneedling technology in the treatment of acne scars
Alfertshofer, Michael , Kaye, Kai , Frank, Konstantin , Mercado‐Perez, Arnaldo , Hargiss, J. Blade , Cotofana, Sebastian , Frank, Konstantin , Mercado-Perez, Arnaldo, Hargiss, John Blade , Cotofana, Sebastian , Alfertshofer, Michael , Casabona, Gabriela , Green, Jeremy B.

Mayo Clinic

Journal of Cosmetic Dermatology | October 2, 2021 | Volume: 20 | Issue: 11 | Pages: 3482-3491

10.1111/jocd.14502 | PMID 34596936 Get It

AbstractBackgroundCurrent options for the reduction of acne scarring (eg, ablative laser resurfacing) are associated with considerable side effects and limitations in terms of patient population. Percutaneous collagen induction via microneedling poses an alternative treatment method due to its low rates of reported adverse events and side effects.ObjectiveTo assess the safety and effectiveness of microneedling treatments in reducing acne scars.MethodsA total of 22 patients (18 females and 4 males) with a mean age of 38 ± 7.6 years were assessed regarding the appearance of facial acne scarring. Acne scars were assessed via the Acne Scar Assessment Scale (ASAS) and the Goodman and Baron acne scar grading scale before and after two/three treatments. Additionally, the post‐interventional development of side reactions, adverse events, and patient‐reported outcomes (eg, pain/discomfort, skin redness) was reported.ResultsCompared to baseline, the mean ASAS value was improved statistically significantly on average by 1.41 and 1.46 after the second treatment as assessed by the independent raters and the patients, respectively. In patients who received a total of three treatments, a statistically significant mean improvement in ASAS value of 1.35 and 1.66 compared to baseline was assessed by the independent raters and patients, respectively. No unexpected adverse events were reported. The severity and rate of side reactions decreased over the course of this study.ConclusionMicroneedling treatments can pose a safe and effective option in the reduction of acne scarring. In this study, microneedling helped achieving a significant reduction of acne scars while showing high patient safety.
Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group
Hurley, Robert W. , Adams, Meredith C B , Barad, Meredith , Bhaskar, Arun , Bhatia, Anuj , Deer, Timothy R. , Hah, Jennifer M. , Hooten, W. Michael , Lee, David Wonhee, McCormick, Zachary L. , Schneider, Byron J. , Eerd, Maarten van , Zundert, Jan Van , Wallace, Mark S. , Wilson, Sara M, Zhao, Zirong , Chadwick, Andrea , Deer, Tim , Hooten, W Michael , Moon, Jee Youn , Narouze, Samer , Cohen, Steven P , van Zundert, Jan , Hurley, Robert W , Barad, Meredith J , Hah, Jennifer M , Bhatia, Anuj , Kissoon, Narayan , Narouze, Samer , Provenzano, David , Cohen, Steven P.

Mayo Clinic

Pain Medicine | October 1, 2021 | Volume: 22 | Issue: 11 | Pages: 2443-2524

10.1093/pm/pnab281 | PMID 34788462 Get It

Abstract Background The past two decades have witnessed a surge in the use of cervical spine joint procedures including joint injections, nerve blocks and radiofrequency ablation to treat chronic neck pain, yet many aspects of the procedures remain controversial. Methods In August 2020, the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine approved and charged the Cervical Joint Working Group to develop neck pain guidelines. Eighteen stakeholder societies were identified, and formal request-for-participation and member nomination letters were sent to those organizations. Participating entities selected panel members and an ad hoc steering committee selected preliminary questions, which were then revised by the full committee. Each question was assigned to a module composed of 4–5 members, who worked with the Subcommittee Lead and the Committee Chairs on preliminary versions, which were sent to the full committee after revisions. We used a modified Delphi method whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was reached. Before commencing, it was agreed that a recommendation would be noted with >50% agreement among committee members, but a consensus recommendation would require ≥75% agreement. Results Twenty questions were selected, with 100% consensus achieved in committee on 17 topics. Among participating organizations, 14 of 15 that voted approved or supported the guidelines en bloc, with 14 questions being approved with no dissensions or abstentions. Specific questions addressed included the value of clinical presentation and imaging in selecting patients for procedures, whether conservative treatment should be used before injections, whether imaging is necessary for blocks, diagnostic and prognostic value of medial branch blocks and intra-articular joint injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for designating a block as positive, how many blocks should be performed before radiofrequency ablation, the orientation of electrodes, whether larger lesions translate into higher success rates, whether stimulation should be used before radiofrequency ablation, how best to mitigate complication risks, if different standards should be applied to clinical practice and trials, and the indications for repeating radiofrequency ablation. Conclusions Cervical medial branch radiofrequency ablation may provide benefit to well-selected individuals, with medial branch blocks being more predictive than intra-articular injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of false-negatives (ie, lower overall success rate). Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.
Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel
Bhimraj, Adarsh , Morgan, Rebecca L. , Shumaker, Amy Hirsch, Baden, Lindsey R. , Cheng, Vincent Chi‐Chung , Edwards, Kathryn M. , Gandhi, Rajesh T. , Gallagher, Jason C , Wollins, Dana S., Falck–Ytter, Yngve , Morgan, Rebecca L , Muller, William J. , O’Horo, John C. , Shoham, Shmuel

Mayo Clinic

Clinical Infectious Diseases | October 1, 2021 | Volume: 74 | Issue: 9 | Pages: 1691-1695

10.1093/cid/ciab882 | PMID 34668008 Get It

Abstract Despite the challenges of the pandemic, there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies. Pivotal COVID-19 trials like SOLIDARITY, RECOVERY, and ACCT-1 were rapidly conducted and data disseminated to support effective therapies. However, critical shortcomings remain on trial conduct, dissemination and interpretation of study results, and regulatory guidance in pandemic settings. The lessons that we learned have implications for both the current pandemic and future emerging infectious diseases. There is a need for establishing and standardizing clinical meaningful outcomes in therapeutic trials and for targeting defined populations and phenotypes that will most benefit from specific therapies. Standardized processes should be established for rapid and critical data review and dissemination to ensure scientific integrity. Clarity around the evidence standards needed for issuance of both emergency use authorization (EUA) and biologic license application (BLA) should be established and an infrastructure for executing rapid trials in epidemic settings maintained.
Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords
Bhimraj, Adarsh , Morgan, Rebecca L. , Shumaker, Amy Hirsch, Lavergne, Valéry , Baden, Lindsey R. , Edwards, Kathryn M. , Gandhi, Rajesh T. , Gallagher, Jason C , Wollins, Dana S., Falck–Ytter, Yngve , Morgan, Rebecca L , Cheng, Vincent Chi‐Chung , Muller, William J. , O’Horo, John C. , Shoham, Shmuel

Mayo Clinic

Clinical Infectious Diseases | October 1, 2021 | Volume: 74 | Issue: 9 | Pages: 1686-1690

10.1093/cid/ciab880 | PMID 34668010 Get It

Abstract Given the urgent need for treatments during the coronavirus disease 2019 pandemic, the US Food and Drug Administration issued emergency use authorizations (EUAs) for multiple therapies. In several instances, however, these EUAs were issued before sufficient evidence of a given therapy’s efficacy and safety were available, potentially promoting ineffective or even harmful therapies and undermining the generation of definitive evidence. We describe the strengths and weaknesses of the different therapeutic EUAs issued during this pandemic. We also contrast them to the vaccine EUAs and suggest a framework and criteria for an evidence-based, trustworthy, and publicly transparent therapeutic EUA process for future pandemics.
Detrusor overactivity assessment using ultrasound bladder vibrometry
Rosen, David , Husmann, Douglas A. , Mynderse, Lance A. , Kelly, Troy F, Fatemi, Mostafa , Rosen, David P , Alizad, Azra , Fatemi, Mostafa , Alizad, Azra

Mayo Clinic

Physiological Measurement | October 1, 2021 | Volume: 42 | Issue: 10 | Pages: 105012

10.1088/1361-6579/ac2c5c | PMID 34598174 Get It

Abstract Objective . Detrusor overactivity (DO) is a urodynamic observation characterized by fluctuations in detrusor pressure ( P det ) of the bladder. Although detecting DO is important for the management of bladder symptoms, the invasive nature of urodynamic studies (UDS) makes it a source of discomfort and morbidity for patients. Ultrasound bladder vibrometry (UBV) could provide a direct and noninvasive means of detecting DO, due to its sensitivity to changes in elasticity and load in the bladder wall. In this study, we investigated the feasibility and applying UBV toward detecting DO. Approach . UBV and urodynamic study (UDS) measurements were collected in 76 neurogenic bladder patients (23 with DO). Timestamped group velocity squared ( c g 2 ) data series were collected from UBV measurements. Concurrent P det data series were identically analyzed for comparison and validation. A processing approach is developed to separate transient fluctuations in the data series from the larger trend of the data and a DO index is proposed for characterizing the transient peaks observed in the data. Main Results. Applying the DO index as a classifier for DO produced sensitivities and specificities of 0.70 and 0.75 for c g 2 data series and 0.70 and 0.83 for P det data series respectively. Significance . It was found that DO can be feasibly detected from data series of timestamped UBV measurements. Collectively, these initial results are promising, and further refinement to the UBV measurement process is likely to improve and clarify its capabilities for noninvasive detection of DO.
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials
Ganzel, Chezi , Lee, Ju‐Whei , Fernández, Hugo F. , Paietta, Elisabeth , Luger, Selina M. , Lazarus, Hillard M. , Cripe, Larry D., Douer, Dan , Wiernik, Peter H. , Rowe, Jacob M. , Tallman, Martin S. , Litzow, Mark R. , Lazarus, Hillard M , Fernandez, Hugo

Mayo Clinic

Blood Advances | October 1, 2021 | Volume: 5 | Issue: 22 | Pages: 4560-4568

10.1182/bloodadvances.2021004999 | PMID 34597373 Get It

Abstract Central nervous system (CNS) involvement in patients with newly diagnosed acute myeloid leukemia (AML) is rare, and systematic data regarding outcome are scarce. This retrospective study summarized data from 11 consecutive Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) clinical trials for patients with newly diagnosed AML. In all, 3240 patients with AML were analyzed, and 36 (1.11%) were found to have CNS involvement at diagnosis. The incidence of CNS disease among the 5 studies with per protocol mandatory lumbar puncture (LP) was similar to the incidence among studies in which LP was performed at the discretion of the investigator (0.86% vs 1.41%; P = .18). There was no significant difference in the rate of complete remission (CR) among patients with CNS involvement and those with other extramedullary disease (EMD) sites or those with no EMD (52.8% vs 59.3%-60%). The median overall survival (OS) for patients who were CNS positive, who had other EMD, or who had no EMD was 11.4, 11.3, and 12.7 months, respectively. There was no difference in OS among patients with CNS involvement, those with other EMD (hazard ratio [HR], 0.96; adjusted P = .84), and those with no EMD (HR, 1.19; adjusted P = .44). In conclusion, the reported incidence of CNS involvement in patients with newly diagnosed AML is low (1.1%), irrespective of whether an LP is mandatory or not. The presence of CNS disease at diagnosis in and of itself does not seem to portend a poor prognosis for achieving an initial CR or for OS.
Postpancreatectomy Acute Pancreatitis (PPAP)
Barreto, Savio George , Bannone, Elisa , Sarr, Michael G., Vollmer, Charles M., Wolfgang, Christopher L. , Zyromski, Nicholas J. , Yeo, Charles J. , Adham, Mustapha, Takaori, Kyoichi , Hilal, Mohammad Abu , Loos, Martin , Hackert, Thilo , Strobel, Oliver , Lillemoe, Keith D. , Miao, Yi , Werner, Jens , Friess, Helmut , Izbicki, Jakob R. , Bockhorn, Maximillian, Vashist, Yogesh K. , Conlon, Kevin C. , Passas, Ioannis , Chiaro, Marco Del , Schulick, Richard D. , Montorsi, Marco , Oláh, Attila , Fusai, Giuseppe , Serrablo, Alejandro , Zerbi, Alessandro , Padbury, Robert, Dervenis, Christos, Bassi, Claudio , Büchler, Markus W., Shrikhande, Shailesh V. , Surgery, on behalf of the International Study Group for Pancreatic, Sarr, Michael, Strobel, Oliver , Marchegiani, Giovanni , Connor, Saxon J. , Falconi, Massimo , Besselink, Marc G , Salvia, Roberto , Siriwardena, Ajith K. , Probst, Pascal , Busch, Olivier R , Halloran, Christopher Michael , Gianotti, Luca Vittorio , Fingerhut, Abe L. , Andersson, Roland E. , Neoptolemos, John P. , Surgery, on behalf of the International Study Group for Pancreatic

Mayo Clinic

Annals of Surgery | October 1, 2021 | Volume: 275 | Issue: 4 | Pages: 663-672

10.1097/sla.0000000000005226 | PMID 34596077 Get It

Objective: The ISGPS aimed to develop a universally accepted definition for PPAP for standardized reporting and outcome comparison. Background: : PPAP is an increasingly recognized complication after partial pancreatic resections, but its incidence and clinical impact, and even its existence are variable because an internationally accepted consensus definition and grading system are lacking. Methods: The ISGPS developed a consensus definition and grading of PPAP with its members after an evidence review and after a series of discussions and multiple revisions from April 2020 to May 2021. Results: We defined PPAP as an acute inflammatory condition of the pancreatic remnant beginning within the first 3 postoperative days after a partial pancreatic resection. The diagnosis requires (1) a sustained postoperative serum hyperamylasemia (POH) greater than the institutional upper limit of normal for at least the first 48 hours postoperatively, (2) associated with clinically relevant features, and (3) radiologic alterations consistent with PPAP. Three different PPAP grades were defined based on the clinical impact: (1) grade postoperative hyperamylasemia, biochemical changes only; (2) grade B, mild or moderate complications; and (3) grade C, severe life-threatening complications. Discussions: The present definition and grading scale of PPAP, based on biochemical, radiologic, and clinical criteria, are instrumental for a better understanding of PPAP and the spectrum of postoperative complications related to this emerging entity. The current terminology will serve as a reference point for standard assessment and lend itself to developing specific treatments and prevention strategies.
Twin Root Replacement in Congenital Heart Disease: Expert Technique
Krishnan, Prasad , Overman, David M. , Stephens, Elizabeth H. , Pochettino, Alberto , Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 1, 2021 | Volume: 12 | Issue: 5 | Pages: 649-653

10.1177/21501351211035787 | PMID 34597207 Get It

In adult congenital heart disease, there are situations that require both the aortic and pulmonary roots to be replaced at the time of a reoperation. This commonly involves the replacement of a previously implanted right ventricle-pulmonary artery conduit in a patient with late aortic root dilation and/or neo-aortic valve dysfunction following the Ross procedure. Similar scenarios are encountered in patients having undergone previous repair of conotruncal anomalies such as truncus arteriosus and tetralogy of Fallot with pulmonary atresia. We describe our standardized technique for twin root replacement.